Treatment options for patients with colorectal cancer (CRC) have increased in the last years.
However, there are no validated prospective molecular markers in CRC to select which agents
are better to treat any individual case. The conventional first-line treatment in CRC
patients in clinical studies get a proportion of patients free of progression at 12 months
ranging from 35-40% with a median of 9 months of free disease progression.
The aim of this study is to demonstrate that the identification of therapeutic targets in
real time and their prospectively use to customize the treatment get a proportion of
colorectal metastatic patients patients free of progression disease at 12 months of 50%.